Date: 2011-02-15
Type of information: Collaboration agreement
Compound: hit identification platform
Company: Evotec (Germany) ChemBridge (USA)
Therapeutic area:
Type agreement: Collaboration
Action mechanism:
Disease:
Details: Evotec has entered into a collaboration with ChemBridge, to further enhance its screening library. This collaboration demonstrates Evotec’s continued improvement to its industry leading hit identification platform. Evotec’s library of 250,000 drug-like and lead-like compounds is available to clients for screening and differentiated itself from other screening libraries through quality, diversity and novelty.Through this collaboration, Evotec will increase its high throughput screening collection through the addition of initially 110,000 diverse and lead-like compounds from the ChemBridge Library Collection. These new compounds complement the chemical diversity of Evotec’s existing collection and will further enhance the quality of the hits provided to our partners.
Financial terms: Financial details of the agreement were not disclosed.
Latest news:
